Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.
about
michGranulopoiesis-stimulating factors for preventing infections after autologous peripheral stem cell transplantation for lymphoma and multiple myeloma in adultsGranulopoiesis-stimulating factors for preventing infections after autologous peripheral stem cell transplantation for lymphoma and multiple myeloma in adultsHigh-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adultsInterferon-alpha for maintenance of follicular lymphomaAllogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older PatientsThe Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs EraReappraising the timing of transplant for indolent non-Hodgkin lymphomas.Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registryReduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study.Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.Controversies and recent advances in hematopoietic cell transplantation for follicular non-hodgkin lymphomaMyeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: potential benefit in second relapseIndications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party.Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.Myeloablative anti-CD20 radioimmunotherapy +/- high-dose chemotherapy followed by autologous stem cell support for relapsed/refractory B-cell lymphoma results in excellent long-term survival.Hematopoietic stem cell transplantation for the management of follicular lymphomaLong-term survival and late relapse in 2-year survivors of autologous haematopoietic cell transplantation for Hodgkin and non-Hodgkin lymphoma.Role of hematopoietic stem cell transplant in the management of follicular lymphoma.Autologous transplant of follicular lymphoma in the era of rituximab.Expanded use of rituximab in the management of non-Hodgkin lymphoma.Optimal application of antibodies in the treatment of follicular lymphoma: current standards and future strategies.Transplantation for non-Hodgkin lymphoma.Hematopoietic cell transplantation for lymphomas.Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials.Follicular lymphoma: current management and future directions.Reappraising the role of autologous transplantation for indolent B-cell lymphomas in the chemoimmunotherapy era: is it still relevant?Current and future management of follicular lymphoma.ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).How we manage follicular lymphoma.Current status of haematopoietic autologous stem cell transplantation in lymphoid malignancies: a European perspective.Autologous hematopoietic cell transplantation: an update for clinicians.Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience.Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas.Life expectancy of young adults with follicular lymphoma.Update on the role of autologous hematopoietic stem cell transplantation in follicular lymphomaPhase II study of autologous stem cell transplant using busulfan-melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphoma.Cost-effectiveness of hematopoietic stem cell mobilization strategies including plerixafor in multiple myeloma and lymphoma patients.SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma.Incidence, risk factors and outcome of histological transformation in follicular lymphoma.
P2860
Q24186266-A4E6A010-02CC-47F8-AFB3-34FF697EBB60Q24200850-7600F811-21E8-43E6-BAEA-AD303864E850Q24203878-6FC447A7-8DF3-466E-8FAC-83E0FC8D67A4Q24240781-357FEF12-A08A-4E41-AE8E-3D87F06555ADQ28066710-9372E291-23D3-48B2-AFDA-B65C2F8760A2Q28072397-A44AB5C1-A601-4262-8AC9-60AD53E84CE7Q30248407-BDD18AF4-C090-47E1-8E55-9CD34C8FC8C7Q33664022-71FD61AF-E1BC-42EC-899A-40CA84520D10Q35100217-DFB9C6D1-0CB8-46E2-9023-763D3CB29786Q35143466-B83AD97C-76B5-4DC2-A59B-A855FBCCAAA2Q36264884-40EAE419-38DC-428A-A52F-E227DFE0468FQ36336614-4A3E3F66-41AB-41EE-9309-4FCD908629D0Q36862529-6E6B4390-CE3C-43BB-A83F-672DD1C926DCQ36967098-27E1593C-E5EA-4A48-A167-ADBA078084D4Q36967144-5E4EA931-24B9-4624-B8E4-3185D73F0C37Q37132248-A9223B90-E6E0-45B6-B4B3-768787F71B29Q37194061-18BC8EF8-4425-462A-BD51-09261C9CC364Q37356389-C88799F9-BD62-4FC9-9309-1C1CFE2E1EACQ37533977-55F32D55-1A3C-41DD-AD5A-1E0B9B03582EQ37742624-07D8369D-58D2-483F-994F-ABC59EE79A34Q37771248-3A189320-A48F-4CC5-BE65-D5F623EAAB5CQ37773249-592A3E99-D0D5-4FEA-9E46-1314A7A5C362Q37810079-59A8D4D8-2A7B-4089-87C7-065CDA9C9848Q37942817-0934A026-D446-427B-B4FD-5259D119C356Q37948748-2821532C-2FE0-45FA-A4FC-98A99B087DD2Q38019789-424D3F91-9AB1-4445-A59E-163EA891FA7EQ38045706-630D3B05-0B70-4A79-A0F9-D72C1F3ABDB0Q38056393-EE15B437-DA17-44CC-83C7-A84F5E0AD852Q38061883-518BDC02-BA45-425B-A20E-B4A5387C828FQ38191811-2C0C469F-8250-47E5-A1DB-AFBF1195F457Q38209433-D6F28BEC-058E-436C-AA5E-D3C9D1CC7DA4Q38248359-C74909F8-6324-49C2-801A-A0531472DC46Q39685859-A07A9969-19B8-4088-999D-A2F345561711Q40015002-D91F79AD-748F-4637-8CE4-D0464261B661Q41370330-A17DE0B7-C700-4921-AB83-F97C74F6BF60Q42142703-EEF0F011-F545-456A-ADE0-C2E122E63C1FQ43135381-8EBE2CC1-1B20-4686-A873-D25A1CA65A19Q44736591-EC04776E-C663-4636-8985-A317D3F52DFEQ44908024-56277DBF-B685-4217-8EEB-53FA2D105781Q45286370-9F8D099C-6F19-4CF6-8FE0-3B0E355F6E79
P2860
Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Impact of rituximab and/or hig ...... icular lymphoma: a GELA study.
@en
Impact of rituximab and/or hig ...... icular lymphoma: a GELA study.
@nl
type
label
Impact of rituximab and/or hig ...... icular lymphoma: a GELA study.
@en
Impact of rituximab and/or hig ...... icular lymphoma: a GELA study.
@nl
prefLabel
Impact of rituximab and/or hig ...... icular lymphoma: a GELA study.
@en
Impact of rituximab and/or hig ...... icular lymphoma: a GELA study.
@nl
P2093
P356
P1476
Impact of rituximab and/or hig ...... licular lymphoma: a GELA study
@en
P2093
Bertrand Coiffier
Bertrand Souleau
Catherine Sebban
Hervé Tilly
Nicole Brousse
Pauline Brice
Philippe Solal-Céligny
Pierre Feugier
Richard Delarue
P304
P356
10.1200/JCO.2007.15.5358
P407
P577
2008-06-16T00:00:00Z